Ezetimibe and Rosuvastatin Combination Treatment Can Reduce the Dose of Rosuvastatin Without Compromising Its Lipid-lowering Efficacy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rhee, Moo-Yong | - |
dc.contributor.author | Kim, Kyung-Jin | - |
dc.contributor.author | Kim, Sang-Hyun | - |
dc.contributor.author | Yoon, Young Won | - |
dc.contributor.author | Rha, Seung-Woon | - |
dc.contributor.author | Hong, Soon Jun | - |
dc.contributor.author | Kwak, Choong-Hwan | - |
dc.contributor.author | Kim, Weon | - |
dc.contributor.author | Nam, Chang-Wook | - |
dc.contributor.author | Park, Tae-Ho | - |
dc.contributor.author | Hong, Taek-Jong | - |
dc.contributor.author | Park, Sungha | - |
dc.contributor.author | Ahn, Youngkeun | - |
dc.contributor.author | Lee, Namho | - |
dc.contributor.author | Jeon, Hui-Kyung | - |
dc.contributor.author | Jeon, Dong Woon | - |
dc.contributor.author | Han, Kyoo-Rok | - |
dc.contributor.author | Moon, Keon-Woong | - |
dc.contributor.author | Chae, In-Ho | - |
dc.contributor.author | Kim, Hae-Young | - |
dc.contributor.author | Kim, Hyo-Soo | - |
dc.date.accessioned | 2021-08-31T22:58:00Z | - |
dc.date.available | 2021-08-31T22:58:00Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2019-12 | - |
dc.identifier.issn | 0149-2918 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/61525 | - |
dc.description.abstract | Purpose: The goal of this study was to compare the lipid-lowering efficacy of the combination of ezetimibe and low- or intermediate-intensity statin therapy versus that of high-intensity statin monotherapy. Methods: This study is a post hoc analysis of an 8 week, randomized, double-blind, Phase III trial. Patients who had hypercholesterolemia and required lipid-lowering treatment were randomly assigned to 1 of 6 treatment groups: rosuvastatin 5 mg (R5, n = 68), rosuvastatin 10 mg (R10, n = 67), rosuvastatin 20 mg (R20, n = 69), and ezetimibe 10 mg combined with rosuvastatin 5 mg (R5 + E10, n = 67), rosuvastatin 10 mg (R10 + E10, n = 68), and rosuvastatin 20 mg (R20 + E10, n = 68) daily. The effects of coadministration of ezetimibe and a low dose of rosuvastatin on lipid parameters and the target achievement rate were compared between the R5 + E10 and R10 treatment groups, the R5 + E10 and R20 treatment groups, and the R10 + E10 and R20 treatment groups. Findings: Reductions in total cholesterol, LDL-C, apolipoprotein B, the apolipoprotein B/A1 ratio, and non HDL-C were not different between the R5 + E10 and R10 treatment groups (all, P > 0.017), the R5 + E10 and R20 treatment groups (all, P > 0.017), and the R10 + E10 and R20 treatment groups (all, P > 0.017). R5 + E10 treatment showed efficacy comparable to that of R10 or R20 in affording LDL levels <50% of the baseline level (R5 + E10 vs R10, 73.13% vs 62.69% [P = 0.1952]; R5 + E10 vs R20, 73.13% vs 73.91% [P = 0.9180]), LDL-C levels <70 mg/dL (R5 + E10 vs R10, 64.18% vs 55.22% [P = 0.2906]; R5 + E10 vs R20, 64.18% vs 62.32% [P = 0.8220]), and LDL-C levels <50% of the baseline level or <70 mg/dL (R5 + E10 vs R10, 77.61% vs 70.15% [P = 0.3255]; R5 + E10 vs R20, 77.61% vs 78.26% [P = 0.9273]). The R10 + E10 treatment group was better than the R20 treatment group in achieving the target LDL-C level <70 mg/dL (83.82% vs 62.32%; P =- 0.0046), even among participants with a baseline LDL-C level >135 mg/dL (77.5% vs 48.8%, respectively; P = 0.0074). Implications: Ezetimibe combined with low- or intermediate-intensity statin therapy has lipid-lowering efficacy comparable to or better than that of high-intensity rosuvastatin monotherapy. The results of the present study indicate that the combination treatment with ezetimibe is advantageous in that it permits dose reduction of rosuvastatin without compromising the lipid-lowering efficacy of rosuvastatin. (C) 2019 Published by Elsevier Inc. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER | - |
dc.subject | DENSITY-LIPOPROTEIN CHOLESTEROL | - |
dc.subject | STATIN THERAPY | - |
dc.subject | LDL-C | - |
dc.subject | RISK | - |
dc.subject | MANAGEMENT | - |
dc.title | Ezetimibe and Rosuvastatin Combination Treatment Can Reduce the Dose of Rosuvastatin Without Compromising Its Lipid-lowering Efficacy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Rha, Seung-Woon | - |
dc.contributor.affiliatedAuthor | Hong, Soon Jun | - |
dc.contributor.affiliatedAuthor | Kim, Hae-Young | - |
dc.identifier.doi | 10.1016/j.clinthera.2019.10.010 | - |
dc.identifier.scopusid | 2-s2.0-85075495974 | - |
dc.identifier.wosid | 000505107100012 | - |
dc.identifier.bibliographicCitation | CLINICAL THERAPEUTICS, v.41, no.12, pp.2571 - 2592 | - |
dc.relation.isPartOf | CLINICAL THERAPEUTICS | - |
dc.citation.title | CLINICAL THERAPEUTICS | - |
dc.citation.volume | 41 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 2571 | - |
dc.citation.endPage | 2592 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | DENSITY-LIPOPROTEIN CHOLESTEROL | - |
dc.subject.keywordPlus | STATIN THERAPY | - |
dc.subject.keywordPlus | LDL-C | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordAuthor | Combination therapy | - |
dc.subject.keywordAuthor | Ezetimibe | - |
dc.subject.keywordAuthor | Hypercholesterolemia | - |
dc.subject.keywordAuthor | Rosuvastatin | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.